Kairos Pharma Secures Exclusive Global Rights to Promising AI-Designed EGFR Inhibitor CL-273 in Strategic Acquisition Deal
“Kairos Pharma, a clinical-stage biopharmaceutical company listed on the NYSE American under the ticker KAPA, has entered into binding terms to acquire exclusive worldwide rights to CL-273, an investigational pan-EGFR inhibitor developed by Celyn Therapeutics. This AI-designed, wild-type-sparing compound targets EGFR-mutant non-small cell lung cancer (NSCLC), addressing key resistance challenges in a market valued at … Read more